Author

Buse Cevatemre

Koç UniversityORCID 0000-0002-0437-6385Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

Adam P. CribbsiD· 2 shared Ceyda AçılaniD· 2 shared Hamzah SyediD· 2 shared Martin PhilpottiD· 2 shared Nareg Pinarbasi DegirmenciiD· 2 shared Tugba Bagci OnderiD· 2 shared Udo C. T. OppermanniD· 2 shared Ahmet CingöziD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adam P. CribbsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 11, 2026

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastoma

Feridun Aksu, Buse Cevatemre, Nareg Pinarbasi Degirmenci…·Tugba Bagci Onder

The paper identifies HDAC6 as an epigenetic vulnerability in TMZ-resistant glioblastoma models and shows HDAC6 inhibitors can restore TMZ sensitivity.

DOI 10.64898/2026.05.07.723296

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell Death and DiseasePeer-reviewedAug 8, 2025

Epidrug Screening Identifies Type I PRMT Inhibitors as Modulators of Lysosomal Exocytosis and Drug Sensitivity in Cancers

Baris Sergi, Neslihan Yuksel-Catal, Selahattin Can Özcan…·Ceyda Acilan

This paper screens epigenetic drugs to identify Type I PRMT inhibitors that inhibit lysosomal exocytosis and enhance chemotherapy efficacy in cancer.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyExperimental & Molecular MedicinePeer-reviewedJun 29, 2025

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

Ozlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz…·Tugba Bagci Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

10 citations

humanbulk RNA-seq

𝕏 PostBluesky